Chemical Genomics: Undruggables and the Quest for Therapeutics from thescientistllc on Vimeo.

When the human genome was mapped in the early 2000s, researchers hoped that that knowing the blueprint of every disease-associated protein in the body would swiftly lead to treatments. Although mapping the human genome helped uncover various disease-associated proteins, almost two decades later, it’s clear that the complex biology of disease, combined with the endless task of screening small molecules, means that many of these targets remain undruggable. However, chemical genomics, defined as the systematic screening of small molecule libraries against various drug target families, promises to remedy this vast gap in therapeutics. Numerous high-throughput screening assays and chemical probes are employed in chemical genomics, many of which have been adapted from large-scale technologies within the pharmaceutical industry. To learn more about chemical genomics and the advances and promises it brings to therapeutic discovery, The Scientist is...

Topics to be covered:

  • Roadblocks and opportunities for protected open innovation in pharmaceutical R&D
  • Patient-led approaches to identify novel targets with chemical genomics

Meet the Speakers:

Mel Reichman, PhD
Senior Investigator, Director, Chemical Genomics Center
CSO Small Molecule R&D
Lankenau Institute for Medical Research (LIMR)

John P. Overington, PhD
Chief Informatics Officer
Catapult Medicines Discovery, UK

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?